All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network
During the 2nd How to Diagnose & Treat CML / MPN, the MPN Hub spoke to Ruben Mesa, UT Health San Antonio, San Antonio, US. We asked, What are the promising new agents for patients with myelofibrosis?
What are the promising new agents for patients with myelofibrosis?
In this video, Mesa outlines the new agents available for the treatment of patients with myelofibrosis, including the JAK inhibitors ruxolitinib and fedratinib, and another two JAK inhibitors currently under development, momelotinib and pacritinib. Mesa then moves on to discuss other options beyond JAK inhibition, including CPI-0610, navitoclax, imetelstat, bomedemstat, and luspatercept.
What do the preliminary results of the MANIFEST trial say about CPI-0610 in treating MF?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Alessandro Vannucchi, University of Florence, IT, about...
Editorial theme | The management of relapsed/refractory myelofibrosis: Part 3 – treatment options beyond JAK inhibition
There is an ongoing effort to develop novel approaches with different modes of action to fulfil an unmet need when Janus kinase...
Subscribe to get the best content related to MPN delivered to your inbox